Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes

NCT02814838 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT02814838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02814838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2016
Completion date
May 15, 2019
Enrollment
76 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, insulin-dependent